Albiglutide Protects Rat Heart from Injury
Author Information
Author(s): Bao Weike, Aravindhan Karpagam, Alsaid Hasan, Chendrimada Thimmaiah, Szapacs Matthew, Citerone David R., Harpel Mark R., Willette Robert N., Lepore John J., Jucker Beat M.
Primary Institution: GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America
Hypothesis
Albiglutide may protect the heart against ischemia/reperfusion injury by increasing carbohydrate utilization and improving cardiac energetic efficiency.
Conclusion
Albiglutide reduced myocardial infarct size and improved cardiac function and energetics following myocardial ischemia/reperfusion injury.
Supporting Evidence
- Albiglutide significantly reduced infarct size and improved cardiac function.
- The treatment increased cardiac glucose uptake and reduced lactate efflux.
- Metabolic gene expression analysis indicated upregulation of key glucose metabolism genes.
Takeaway
Albiglutide helps the heart heal better after it gets hurt by improving how it uses energy and sugar.
Methodology
Sprague-Dawley rats were treated with albiglutide and subjected to myocardial ischemia followed by reperfusion, with measurements of infarct size and cardiac function.
Potential Biases
All authors are employees of GlaxoSmithKline, which may introduce bias in the study.
Limitations
The study was conducted in a rodent model, which may not fully translate to humans.
Participant Demographics
Male Sprague-Dawley rats were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website